FarmaKology-Ultrasound-triggered nanocatchers turn tumors into personalized vaccines

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+21K Subs.

Jan 13, 2026

Today's Company

PharmaEssentia

PharmaEssentia was born in 2003 from a bold scientific vision: that the fusion of biology and synthetic organic chemistry could unlock a new generation of breakthrough therapies. Driven by this belief, our founder invested his life savings, brought together a small circle of scientific pioneers, and established PharmaEssentia in a modest office at Taipei’s Nangang Software Park. From the beginning, our mission has been clear—to harness the power of innovation to tackle complex diseases and improve lives around the world. What started as a small, determined effort has grown into a global biopharmaceutical company, grounded in rigorous science, and guided by the same pioneering spirit that inspired our founding. What started as a bold dream has since become a beacon of innovation and hope—proof that one person’s conviction can spark a transformation far beyond their time and place.

News

ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development

ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, and Foundation Medicine, a global, patient-focused precision medicine company, announced a collaboration to combine their data assets for life sciences research. The collaboration brings Foundation Medicine’s expansive de-identified multimodal dataset derived from its genomic testing portfolio together with ConcertAI’s high-quality clinical data, to support more efficient drug development and real-world evidence research. With the addition of Foundation Medicine’s data, ConcertAI now offers the largest and most comprehensive clinically-linked dataset with nearly half a million patients.

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (generic name, marketed as IBTROZI^® in the U.S. and Japan). Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan.

NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI

NVIDIA and Eli Lilly and Company announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry. The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with NVIDIA’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab. Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from NVIDIA, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using NVIDIA BioNeMo™ as the critical platform.

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug

The GARDP Foundation and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio 1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished.

BioMed X Launches XBridge Pilot to Facilitate Industry-Academic Research Collaborations

BioMed X announced today the launch of a pilot initiative with Harvard University under BioMed X’s XBridge framework to support structured research collaborations between academic investigators and pharmaceutical industry scientists through sponsored research agreements. The XBridge pilot is designed to connect senior biomedical researchers and principal investigators at Harvard with researchers from pharmaceutical companies seeking to explore collaborative research opportunities. The initiative aims to provide a transparent and structured mechanism for identifying areas of shared scientific interest and enabling dialogue that may lead to formal sponsored research collaborations facilitated by the Harvard Office of Technology Development.